R.H. Bluestein & Co’s Hologic HOLX Stock Holding History

R.H. Bluestein & Co’s Portfolio HOLX Stock Details HOLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$291K	–	417
2020 Q4	$291K	Hold	4,000	–	–	0.01%	293
2020 Q3	$266K	Hold	4,000	–	–	0.01%	269
2020 Q2	$228K	Buy	+4,000	New	+$196K	0.01%	289
2018 Q2	–	Sell	-7,800	Closed	-$291K	–	318
2018 Q1	$291K	Buy	+7,800	New	+$315K	0.02%	253

Other funds holding HOLX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

R.H. Bluestein & Co's HOLX Position: Q1 2021 in Review

R.H. Bluestein & Co sold out of Hologic (HOLX) in Q1 2021, closing a stake of 4,000 shares — an estimated $291K sold.

R.H. Bluestein & Co first reported a position in HOLX in Q1 2018 and held it in 4 quarters. The position peaked at $291K in Q4 2020. 638 funds tracked by Wall St. Rank hold HOLX as of Q1 2021.

R.H. Bluestein & Co reported no remaining Hologic position as of Q1 2021 after selling out during the quarter.
R.H. Bluestein & Co sold 4,000 Hologic shares in Q1 2021, an estimated $291K.
R.H. Bluestein & Co first reported a position in Hologic in Q1 2018 and held it in 4 quarters.
R.H. Bluestein & Co's Hologic position peaked at $291K in Q4 2020.
638 funds tracked by Wall St. Rank held Hologic as of Q1 2021.

Based on R.H. Bluestein & Co's 13F filing for Q1 2021, filed 12 May 2021.